{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T19:33:03Z","timestamp":1793215983346,"version":"4.5.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2018,12,11]],"date-time":"2018-12-11T00:00:00Z","timestamp":1544486400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1007\/s00432-018-2819-x","type":"journal-article","created":{"date-parts":[[2018,12,11]],"date-time":"2018-12-11T05:20:37Z","timestamp":1544505637000},"page":"511-521","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":187,"title":["Immune-related adverse events correlate with improved survival in patients undergoing anti-PD1 immunotherapy for metastatic melanoma"],"prefix":"10.1007","volume":"145","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8686-4106","authenticated-orcid":false,"given":"Alice","family":"Indini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenza","family":"Di Guardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina","family":"Cimminiello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Prisciandaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Randon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filippo","family":"De Braud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Del Vecchio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,12,11]]},"reference":[{"key":"2819_CR1","doi-asserted-by":"publisher","first-page":"2658","DOI":"10.1038\/sj.jid.5700545","volume":"126","author":"PD Boasberg","year":"2006","unstructured":"Boasberg PD, Hoon DS, Piro LD et al (2006) Enhanced survival associated with vitiligo expression during maintenance biotherapy for metastatic melanoma. J Invest Dermatol 126:2658\u20132663","journal-title":"J Invest Dermatol"},{"key":"2819_CR2","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1097\/CJI.0000000000000127","volume":"39","author":"S Boudewijns","year":"2016","unstructured":"Boudewijns S, Westdorp H, Koornstra RH et al (2016) Immune-related adverse events of dendritic cell vaccination correlate with immunologic and clinical outcome in stage III and IV melanoma patients. J Immunother 39:241\u2013248","journal-title":"J Immunother"},{"key":"2819_CR3","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1097\/CCO.0b013e328341edff","volume":"23","author":"MG Bouwhuis","year":"2011","unstructured":"Bouwhuis MG, Ten Hagen TL, Suciu S, Eggermont AM (2011) Autoimmunity and treatment outcome in melanoma. Curr Opin Oncol 23:170\u2013176","journal-title":"Curr Opin Oncol"},{"key":"2819_CR4","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","volume":"36","author":"JR Brahmer","year":"2018","unstructured":"Brahmer JR, Lacchetti C, Schneider BJ et al (2018) Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 36:1714\u20131768","journal-title":"J Clin Oncol"},{"key":"2819_CR5","doi-asserted-by":"publisher","first-page":"6681","DOI":"10.1158\/1078-0432.CCR-07-0187","volume":"12","author":"SG Downey","year":"2007","unstructured":"Downey SG, Klapper JA, Smith FO et al (2007) Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade. Clin Cancer Res 12:6681\u20136688","journal-title":"Clin Cancer Res"},{"key":"2819_CR6","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1056\/NEJMoa1802357","volume":"378","author":"AMM Eggermont","year":"2018","unstructured":"Eggermont AMM, Christian UB, Blank MD et al (2018) Adjuvant pembrolizumab versus placebo in resected stage III melanoma. N Engl J Med 378:1789\u20131801","journal-title":"N Engl J Med"},{"key":"2819_CR7","doi-asserted-by":"publisher","first-page":"3977","DOI":"10.1158\/1078-0432.CCR-12-3243","volume":"19","author":"Y Feng","year":"2013","unstructured":"Feng Y, Roy A, Masson E et al (2013) Exposure-response relationships of the efficacy and safety of ipilimumab in patients with advanced melanoma. Clin Cancer Res 19:3977\u20133986","journal-title":"Clin Cancer Res"},{"key":"2819_CR8","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1158\/1078-0432.CCR-15-1136","volume":"22","author":"M Freeman-Keller","year":"2016","unstructured":"Freeman-Keller M, Kim Y, Cronin H (2016) Nivolumab in resected and unresectable metastatic melanoma: characteristics of immune-related adverse events and association with outcomes. Clin Cancer Res 22:886\u2013894","journal-title":"Clin Cancer Res"},{"key":"2819_CR9","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1056\/NEJMoa053007","volume":"354","author":"H Gogas","year":"2006","unstructured":"Gogas H, Ioannovich J, Dafni U et al (2006) Prognostic significante of autoimmunity during treatment of melanoma with interferon. N Engl J Med 354:709\u2013718","journal-title":"N Engl J Med"},{"key":"2819_CR10","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1007\/s10637-017-0476-6","volume":"35","author":"V Heidelberger","year":"2017","unstructured":"Heidelberger V, Goldwasser F, Kramkimel N et al (2017) Clinical parameters associated with anti-programmed death-1 (PD-1) inhibitors-induced tumor response in melanoma patients. Invest New Drugs 35:842\u2013847","journal-title":"Invest New Drugs"},{"key":"2819_CR11","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1003466","volume":"363","author":"FS Hodi","year":"2010","unstructured":"Hodi FS, O\u2019Day SJ, McDermott DF et al (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363:711\u2013723","journal-title":"N Engl J Med"},{"key":"2819_CR12","doi-asserted-by":"publisher","first-page":"3978","DOI":"10.1245\/s10434-014-3794-3","volume":"21","author":"Y Hu","year":"2014","unstructured":"Hu Y, Smolkin ME, White EJ et al (2014) Inflammatory adverse events are associated with disease-free survival after vaccine therapy among patients with melanoma. Ann Surg Oncol 21:3978\u20133984","journal-title":"Ann Surg Oncol"},{"key":"2819_CR13","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1001\/jamadermatol.2015.2707","volume":"152","author":"C Hua","year":"2016","unstructured":"Hua C, Boussemart L, Mateus C (2016) Association of vitiligo with tumor response in patients with metastatic melanoma treated with pembrolizumab. JAMA Dermatol 152:45\u201351","journal-title":"JAMA Dermatol"},{"key":"2819_CR14","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1002\/cncr.24951","volume":"116","author":"G Ku","year":"2010","unstructured":"Ku G, Yuan J, Page D et al (2010) Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting. Cancer 116:1767\u20131775","journal-title":"Cancer"},{"key":"2819_CR15","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1056\/NEJMoa1504030","volume":"373","author":"J Larkin","year":"2015","unstructured":"Larkin J, Chiarion-Sileni V, Gonzalez R et al (2015) Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 373:23\u201334","journal-title":"N Engl J Med"},{"key":"2819_CR16","doi-asserted-by":"crossref","first-page":"77404","DOI":"10.18632\/oncotarget.12677","volume":"7","author":"Y Nakamura","year":"2016","unstructured":"Nakamura Y, Kitano S, Takahashi A et al (2016) Nivolumab for advanced melanoma: pretreatment prognostic factors and early outcome markers during therapy. Oncotarget 7:77404\u201377415","journal-title":"Oncotarget"},{"key":"2819_CR17","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1111\/1346-8138.13520","volume":"44","author":"Y Nakamura","year":"2017","unstructured":"Nakamura Y, Tanaka R, Asami Y et al (2017) Correlation between vitiligo occurrence and clinical benefit in advanced melanoma patients treated with nivolumab: A multi-institutional retrospective study. J Dermatol 44:117\u2013122","journal-title":"J Dermatol"},{"key":"2819_CR18","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1038\/bjc.2017.70","volume":"116","author":"A Nosrati","year":"2017","unstructured":"Nosrati A, Tsai KK, Goldinger SM et al (2017) Evaluation of clinicopathological factors in PD-1 response: derivation and validation of a prediction scale for response to PD-1 monotherapy. Br J Cancer 116:1141\u20131147","journal-title":"Br J Cancer"},{"key":"2819_CR19","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1016\/S1470-2045(15)00083-2","volume":"16","author":"A Ribas","year":"2015","unstructured":"Ribas A, Puzanov I, Dummer R et al (2015) Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncol 16:908\u2013918","journal-title":"Lancet Oncol"},{"key":"2819_CR20","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert C, Schachter J, Long GV et al (2015) Pembrolizumab versus Ipilimumab in Advanced Melanoma. N Engl J Med 372:2521\u20132532","journal-title":"N Engl J Med"},{"key":"2819_CR21","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1200\/JCO.2014.57.4756","volume":"33","author":"HE Teulings","year":"2015","unstructured":"Teulings HE, Limpens J, Jansen SN et al (2015) Vitiligo-like depigmentation in patients with stage III-IV melanoma receiving immunotherapy and its association with survival: a systematic review and meta-analysis. J Clin Oncol 33:773\u2013781","journal-title":"J Clin Oncol"},{"key":"2819_CR22","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1634\/theoncologist.2017-0384","volume":"23","author":"Y Toi","year":"2018","unstructured":"Toi Y, Sugawara S, Kawashima Y et al (2018) Association of immune-related adverse events with clinical benefit in patients with advanced non-small-cell lung cancer treated with nivolumab. Oncologist 23:1358\u20131365","journal-title":"Oncologist"},{"key":"2819_CR23","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","volume":"366","author":"SL Topalian","year":"2012","unstructured":"Topalian SL, Hodi FS, Brahmer JR et al (2012) Safety, activity and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366:2443\u20132454","journal-title":"N Engl J Med"},{"key":"2819_CR24","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.3923","author":"DY Wang","year":"2018","unstructured":"Wang DY, Salem JE, Cohen JV et al (2018) Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis. JAMA Oncol. https:\/\/doi.org\/10.1001\/jamaoncol.2018.3923","journal-title":"JAMA Oncol"},{"key":"2819_CR25","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/S1470-2045(15)70076-8","volume":"16","author":"JS Weber","year":"2015","unstructured":"Weber JS, D\u2019Angelo SP, Minor D et al (2015) Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol 16:375\u2013384","journal-title":"Lancet Oncol"},{"key":"2819_CR26","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1056\/NEJMoa1709030","volume":"377","author":"J Weber","year":"2017","unstructured":"Weber J, Mandala M, Del Vecchio M et al (2017a) Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma. N Engl J Med 377:1824\u20131835","journal-title":"N Engl J Med"},{"key":"2819_CR27","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1200\/JCO.2015.66.1389","volume":"35","author":"JS Weber","year":"2017","unstructured":"Weber JS, Hodi FS, Wolchok JD et al (2017b) Safety profile of nivolumab monotherapy: a pooled analysis of patients with advanced melanoma. J Clin Oncol 35:785\u2013792","journal-title":"J Clin Oncol"},{"key":"2819_CR28","doi-asserted-by":"publisher","first-page":"5487","DOI":"10.1158\/1078-0432.CCR-16-0127","volume":"22","author":"B Weide","year":"2016","unstructured":"Weide B, Martens A, Hassel JC et al (2016) baseline biomarkers for outcome of melanoma patients treated with pembrolizumab. Clin Cancer Res 22:5487\u20135496","journal-title":"Clin Cancer Res"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00432-018-2819-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-018-2819-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-018-2819-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,17]],"date-time":"2020-11-17T07:32:33Z","timestamp":1605598353000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00432-018-2819-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12,11]]},"references-count":28,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,2]]}},"alternative-id":["2819"],"URL":"https:\/\/doi.org\/10.1007\/s00432-018-2819-x","relation":{},"ISSN":["0171-5216","1432-1335"],"issn-type":[{"value":"0171-5216","type":"print"},{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,12,11]]},"assertion":[{"value":"31 October 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 December 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 December 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"This article does not contain any studies with animals performed by any of the authors.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human rights and animal participants"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}